Cibus, Inc.

NASDAQ:CBUS

Biotechnology

Healthcare
$1.23 +3.10%

+$0.04 today

Market cap
$94.01M
Beta
1.65
P/E (TTM)
-8.6
EPS (TTM)
-$0.16
52W Low $1.09High $4.19

Volume 0.19M

Average 0.51M

Returns on capital

Cibus, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-582.2%

avg -160.2%

ROIC

-23.2%

avg -59.6%

ROA

-41.7%

avg -53.4%

Analysis

ROIC is currently the strongest return metric at -23.2% versus its period average of -59.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Rory Balfour Riggs

Co-Founder & DirectorUSD 1.09M73——

Peter Beetham

Co-Founder, President & COOUSD 630.58K63390.00K0.86%

Gregory F. Gocal

Co-Founder, Chief Scientific Officer & Executive Vice PresidentUSD 455.02K57——

Jason Stokes

Chief Administrative Officer, General Counsel & Corporate SecretaryUSD 439.71K55164.35K0.36%

Cornelis Broos

Chief Financial OfficerUSD 238.98K54——

Craig Wichner

Chief Executive OfficerUSD 9.29K56894.31K1.97%

Rosa Cheuk Kim

Senior Vice President of Legal————

Noel Sauer

Senior Vice President of Research—59138.04K0.30%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 11, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+185.1%
+147.3% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at +185.1% over three years. Forward estimates point to Revenue at +147.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Cibus, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CBUS's management, answered from reported figures.

Who manages CBUS?

Cibus, Inc. (CBUS) lists 8 active executives. The top listed executive is Gregory F. Gocal, Co-Founder, Chief Scientific Officer & Executive Vice President.

Are CBUS insiders buying or selling?

Recent insider activity shows net buying of $29.84M.